Projected Lifetime Healthcare Costs Associated with HIV Infection

Abstract

ObjectiveEstimates of healthcare costs associated with HIV infection would provide valuable insight for evaluating the cost-effectiveness of possible prevention interventions. We evaluate the additional lifetime healthcare cost incurred due to living with HIV.MethodsWe used a stochastic computer simulation model to project the distribution of lifetime outcomes and costs of men-who-have-sex-with-men (MSM) infected with HIV in 2013 aged 30, over 10,000 simulations. We assumed a resource-rich setting with no loss to follow-up, and that standards and costs of healthcare management remain as now.ResultsBased on a median (interquartile range) life expectancy of 71.5 (45.0–81.5) years for MSM in such a setting, the estimated mean lifetime cost of treating one person was £360,800 ($567,000 or €480,000). With 3.5% discounting, it was £185,200 ($291,000 or €246,000). The largest proportion (68%) of these costs was attributed to antiretroviral drugs. If patented drugs are replaced by generic versions (at 20% cost of patented prices), estimated mean lifetime costs reduced to £179,000 ($281,000 or €238,000) and £101,200 ($158,900 or €134,600) discounted.ConclusionsIf 3,000 MSM had been infected in 2013, then future lifetime costs relating to HIV care is likely to be in excess of £1 billion. It is imperative for investment into prevention programmes to be continued or scaled-up in settings with good access to HIV care services. Costs would be reduced considerably with use of generic antiretroviral drugs.

The clinical effectiveness of individual behaviour change interventions to reduce risky sexual behaviour after a negative human immunodeficiency virus test in men who have sex with men: systematic and realist reviews and intervention development

“…However, recent estimates of health-care costs associated with HIV infection suggest an estimated mean lifetime cost of treating one person as £360,800. 31 Therefore, if around 3000 men are newly infected each year, new direct lifetime costs relating to their treatment alone will amount to around £1.1B. If generic drugs replace patented drugs, estimated mean lifetime costs could fall to £179,000.…”

Self-sampling kits to increase HIV testing among black Africans in the UK: the HAUS mixed-methods study

“…83 Patients who were HIV positive, receiving ART and adherent with medication, changed viral load and CD4 count in line with the algorithm set out in Nakagawa et al, 83 based on treatment strategy and adherence.…”

“…As mortality is higher in those with HIV, the probability of death from non-HIV-related causes was increased by 50%. 83 The risk of death from non-HIV-related causes was age and sex specific. We conducted a sensitivity analysis that increased the probability of death by 100% for non-HIV-related causes.…”

Mobile phone messaging to promote uptake of HIV testing among migrant African communities in the UK

“…However, mobile phone interventions are low cost. The cost saving for any new HIV case detected in the UK has been estimated at £380,000 (US$ 493,582) (Nakagawa et al, 2015), suggesting that even marginally increasing the potential for identification of new cases through increasing access to testing has potential for significant economic benefit.…”